TY  - JOUR
T1  - BEvacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema
AU  - Rahimy E, Sarraf D
Y1  - 2012/07/01
N1  - 10.1001/archophthalmol.2011.2741
JO  - Archives of Ophthalmology
SP  - 931
EP  - 932
VL  - 130
IS  - 7
N2  - 
Tamoxifen citrate, an oral antiestrogen, is most commonly used in low dosages (20 mg/d) as an adjuvant therapy for breast cancer. At significantly higher dosages (200 mg/d), it has also been used to treat malignant astrocytoma of the brain.1 Of its well-documented ocular toxic effects, potentially the most devastating is the development of crystalline maculopathy with associated cystoid macular edema (CME).2 Treatment consists of cessation of the medication, which may stabilize vision but rarely results in its recovery. We describe the first reported case, to our knowledge, of severe tamoxifen-induced CME resolved with intravitreal bevacizumab (Avastin) therapy.

SN  - 0003-9950
M3  - doi: 10.1001/archophthalmol.2011.2741
UR  - http://dx.doi.org/10.1001/archophthalmol.2011.2741
ER  -